Know Cancer

forgot password

A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer

Phase 1
18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer



- Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with
metastatic breast cancer.

- Identify a tolerable, immunologically active dose level of this vaccine in these


- Evaluate the immune function in these patients before and after treatment with this

OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.

After completion of study treatment, patients are followed monthly for 9 months.

Inclusion Criteria:

- Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the
breast with marrow involvement.

- Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29

- Stable disease (defined as fluctuation of <50U in CA15-3 or CA27-29 value) for at
least 3 months while either on no breast-cancer therapy or while on current therapy
(Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or
trastuzumab chemotherapy is not allowed)

- ability to understand the risks, benefits, and procedures and provide written
informed consent.

- less than 28 days prior to enrollment since last surgery and/or radiation therapy.

- performance status <=2 on the ECOG performance scale and life expectancy of greater
than 12 months

- NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is
abnormal, patient must have an echocardiogram showing a left ventricular ejection
fraction greater than the lower limits of normal.

- patients who do not have radiographically assessable locally recurrent or metastatic
disease are eligible if they 1) had radiographic or biopsy proven locally recurrent
or metastatic breast cancer in the past and 2) currently (at study entry) have an
elevated serum MUC-1 level (as measured by CA 15-3 or CA 27-29).

- Acceptable pulmonary function. if questionable, a pulmonary function test will be

- negative serology for hepatitis B, C and HIV.

- red cell mean corpuscular volume >- 80 cu. mm, hemoglobin >- 8g/dl, platelet count >-
100,000/dl: AST, ALT, LDH <-2 times the Upper limit of normal

- Serum creatinine < 1.6 mg/dL

- for women with child bearing potential, Negative urine pregnancy test within 7 days
of registration and willingness to use an approved contraceptive method while
participating in this trial.

Exclusion Criteria:

- history of bronchospasm or asthma requiring inhaled or oral steroid treatment

- Normal MUC-1 (CA 15-3 or CA 27-29)

- treatment with steroid or other immunosuppressive medication (for any condition )
within 30 days of trial registration.

- history of any autoimmune disease (e.g., lupus, rheumatoid arthritis, or psoriasis)

- uncontrolled diabetes mellitus

- unable or unwilling to undergo repeated clinical evaluations and other diagnostic
procedures or unable to sign an informed consent.

- history of other malignancies, except squamous cell or basal cell carcinoma of the
skin or cervical carcinoma in situ.

- Concurrent systemic chemotherapy (tamoxifen, aromatase inhibitors, fulvestrant,
trastuzumab and biophosphonates are allowed if started more than 3 months prior to
trial registration with evidence of stable disease as defined above. Chemotherapy
must have stopped 3 months prior to enrolling in this trial).

- history of ornithine transcarbamylase deficiency

- any acute or chronic viral, bacterial, or fungal infection requiring specific
therapy, unless acute therapy was completed within the past 14 days

- No underlying conditions that would contraindicate therapy with study treatment ( or
allergies to reagents used in this study)

- history of organ transplant or allogeneic bone marrow transplant

- life threatening or organ-threatening disease expected to require conventional
therapy within 4 months.

- pregnant or nursing females.

Type of Study:


Study Design:

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Characterize the safety profile of the Ad-sig-hMUC-1/ecdCD40L vector vaccine

Safety Issue:


Principal Investigator

Sara Hurvitz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jonsson Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2008

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage IV breast cancer
  • recurrent breast cancer
  • Breast Neoplasms



Jonsson Comprehensive Cancer Center at UCLALos Angeles, California  90095-1781